Novo Nordisk reprimanded for failing to disclose payments of almost £8m to healthcare sector
The decision to publicly reprimand Novo Nordisk was based on hundreds of payments made to more than 150 healthcare organisations, professionals, and members of the public, amounting to £7.8m.
The PMCPA said its Appeal Board described the breach as “extremely serious”
Shutterstock.com
Drug manufacturer Novo Nordisk has been reprimanded by the Prescription Medicines Code Of Practice Authority (PMCPA) for failing to disclose payments of around £7.8m to individuals and organisations in the UK between 2020 and 2022.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
